

Anti-Complement C5 Antibody (Vilobelimab)

Introduction

Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody. The anaphylatoxin C5a is a pro-inflammatory complement split product that plays a central role in mediating organ dysfunction. Vilobelimab can be used as a C5a inhibitor to inhibit neutrophil activation and chemotaxis, reduce inflammatory signals, etc., and can be used in sepsis, COVID-19 and other related studies.

Product parameters

Alternative Names	IFX-1, CaCP29, INab308
Target Accession	P01031
Target	Complement C5
CAS number	2250440-41-4
Molecular Weight	145.88 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4SP
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

